JZP-458

Unassigned

New Medicines

Acute lymphoblastic leukaemia (ALL) or lymphoblastic lymphoma (LBL) in adults and children

Information

New molecular entity
Jazz Pharmaceuticals
Jazz Pharmaceuticals

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

A recombinant Erwinia asparaginase that uses a novel Pseudomonas fluorescens expression platform
ALL is the most common cancer in children. Global incidence is about 3 per 100,000 population, with about 3 out of 4 cases occurring in children aged under 6 years. ALL represents 12% of all leukaemia (but 80% in children). Peak age of incidence occurs between the ages of 2-4 years, decreasing to become a much rarer disease of adulthood. A smaller peak occurs in people aged over 50 years [1].
Acute lymphoblastic leukaemia (ALL) or lymphoblastic lymphoma (LBL) in adults and children
Intramuscular and
Intravenous infusion